Abstract Heart failure (HF) is a major public health problem characterised by high rate of hospitalisation and death. The risk maximal for patients admitted with acute heart (AHF). New therapies solid proof mortality reduction in both groups reduced preserved ejection fraction (EF) are now available (valsartan/sacubitril SGLT 2 inhibitors). purpose this article to review the main data clarify r...

AIMS Serelaxin is effective in relieving dyspnoea and improving multiple outcomes in acute heart failure (AHF). Many AHF patients have preserved ejection fraction (HFpEF). Given the lack of evidence-based therapies in this population, we evaluated the effects of serelaxin according to EF in RELAX-AHF trial. METHODS AND RESULTS RELAX-AHF randomized 1161 AHF patients to 48-h serelaxin (30 μg/kg...

BACKGROUND The Relaxin for the Treatment of Acute Heart Failure (RELAX-AHF) trial enrolled 1161 patients admitted to the hospital for acute heart failure (AHF) to evaluate the therapeutic efficacy of serelaxin, a recombinant form of human relaxin-2. We characterized how representative RELAX-AHF clinical trial enrollees were to those patients with AHF found in international registries. METHODS...

BACKGROUND We evaluated the associations among angiotensin-converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism, ACE activity and post-myocardial infarction (MI) left ventricular dysfunction and acute heart failure (AHF) early after presentation with MI with ST-segment elevation (STEMI). METHODS A total of 556 patients with STEMI treated by primary PCI (421 patients without AHF ...

BACKGROUND AND OBJECTIVES The relationship between ejection fraction (EF), N-terminal pro-brain natriuretic peptide (NT-proBNP) levels and renal function is unknown as stratified by heart failure (HF) type. We investigated their relation and the prognostic value of renal function in heart failure with preserved ejection fraction (HFpEF) vs. reduced ejection fraction (HFrEF). MATERIALS AND MET...

OBJECTIVES The purpose of this study was to examine the clinical effectiveness of aldosterone antagonists in older patients with heart failure and preserved ejection fraction (HF-PEF). BACKGROUND Aldosterone antagonists improve outcomes in HF and reduced EF. However, their role in HF-PEF remains unclear. METHODS Of the 10,570 hospitalized older (65 years of age) HF-PEF (EF 40%) patients in ...

BACKGROUND Although individuals of Hispanic ethnicity are at high risk for developing heart failure (HF), little is known about differences between Hispanic HF patients stratified by left ventricular ejection fraction (EF). We compared characteristics, quality of care, and outcomes between Hispanic and non-Hispanic white patients hospitalized for HF with preserved EF (PEF) or reduced EF (REF). ...

AIMS Pulmonary oedema is a common and important finding in acute heart failure (AHF). We conducted a systematic review to describe the methods used to assess pulmonary oedema in recent randomized AHF trials and report its prevalence in these trials. METHODS AND RESULTS Of 23 AHF trials published between 2002 and 2013, six were excluded because they were very small or not randomized, or missin...